NCT00483106View on ClinicalTrials.gov

Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

PHASE4CompletedINTERVENTIONAL
Enrollment

885

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Ritalin

0.25 mg/kg bid, orally for 7 consecutive days

DRUG

Placebo

taken orally twice a day for 7 consecutive days

Trial Locations (1)

H4H 1R3

Douglas Mental Health University Institute, Montreal

All Listed Sponsors
lead

McGill University

OTHER

NCT00483106 - Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter